|
influenza |
22 |
|
vaccination |
17 |
|
adult |
15 |
|
humans |
15 |
|
medical sciences |
15 |
|
influenza, human - mortality |
14 |
|
disease outbreaks |
13 |
|
influenza a(h5n1) |
13 |
|
middle aged |
13 |
|
adolescent |
11 |
|
child |
11 |
|
child, preschool |
11 |
|
china |
11 |
|
cost-effectiveness analysis |
11 |
|
hong kong - epidemiology |
11 |
|
pandemics |
11 |
|
covid-19 |
10 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
10 |
|
pandemic risk assessment |
10 |
|
patient admission - statistics and numerical data |
10 |
|
population surveillance |
10 |
|
antibodies, viral - blood |
9 |
|
communicable disease control - methods |
9 |
|
cross-sectional studies |
9 |
|
disease outbreaks - statistics & numerical data |
9 |
|
hav |
9 |
|
hbv |
9 |
|
hcv |
9 |
|
hev |
9 |
|
immigration |
9 |
|
immunoglobulin g - blood |
9 |
|
influenza a virus, h1n1 subtype - immunology |
9 |
|
influenza, human - epidemiology - immunology - virology |
9 |
|
markov chains |
9 |
|
monte carlo method |
9 |
|
neutralization tests |
9 |
|
pandemic |
9 |
|
reproducibility of results |
9 |
|
seroepidemiologic studies |
9 |
|
serology |
9 |
|
seroprevalence |
9 |
|
attitudes |
8 |
|
behavior change |
8 |
|
coronavirus disease 2019 |
8 |
|
coughing |
8 |
|
death |
8 |
|
disease predisposition |
8 |
|
disease surveillance |
8 |
|
gastroenterology |
8 |
|
human influenza |
8 |
|
mutation |
8 |
|
avian influenza a(h7n9) |
7 |
|
cervical cancer |
7 |
|
clinical epidemiology |
7 |
|
communicable diseases, emerging - prevention and control - transmission |
7 |
|
grounded theory |
7 |
|
immigrants |
7 |
|
influenza a virus, h7n9 subtype |
7 |
|
influenza a(h7n9) |
7 |
|
influenza in birds - prevention and control - transmission |
7 |
|
influenza, human - prevention and control - transmission |
7 |
|
live poultry markets |
7 |
|
qualitative analysis |
7 |
|
severity |
7 |
|
alcohol drinking |
6 |
|
alcohols |
6 |
|
behavior |
6 |
|
children |
6 |
|
clade 2.3.4.4.b |
6 |
|
cross-reactive antibody response |
6 |
|
depressive symptoms |
6 |
|
enterovirus |
6 |
|
environment-wide association study |
6 |
|
epidemiology |
6 |
|
h1n1 pandemic |
6 |
|
health knowledge, attitudes, practice |
6 |
|
influenza a virus |
6 |
|
influenza a virus, h1n1 subtype |
6 |
|
influenza a virus, h1n1 subtype - isolation and purification |
6 |
|
influenza a virus, h1n1 subtype - physiology |
6 |
|
influenza a(h1n1)pdm09 |
6 |
|
influenza in birds - mortality - transmission |
6 |
|
influenza, human - blood - epidemiology - virology |
6 |
|
influenza, human - epidemiology - prevention & control - transmission |
6 |
|
influenza, human - epidemiology - prevention and control - psychology - virology |
6 |
|
mental well-being |
6 |
|
meta-analysis |
6 |
|
models, biological |
6 |
|
moderate drinkers |
6 |
|
neuraminidase inhibition antibody |
6 |
|
neutralization |
6 |
|
pandemics - statistics and numerical data |
6 |
|
physical well-being |
6 |
|
population surveillance - methods |
6 |
|
psychological and behavioral responses |
6 |
|
residence characteristics - statistics and numerical data |
6 |
|
respiration, artificial - statistics and numerical data |
6 |
|
respiratory infections |
6 |
|
sars coronavirus 2 |
6 |
|
schools |
6 |
|
seasons |
6 |
|
seriousness |
6 |
|
seroepidemiology |
6 |
|
social well-being |
6 |
|
viruses |
6 |
|
excess mortality |
5 |
|
h1n1pdm09 |
5 |
|
human papillomavirus |
5 |
|
impact |
5 |
|
sars-cov-2 |
5 |
|
adcc |
4 |
|
aged |
4 |
|
antibody |
4 |
|
antibody titerarticleblood donor |
4 |
|
aspirin |
4 |
|
bivalent vaccine |
4 |
|
cervical cancer screening |
4 |
|
china - epidemiology |
4 |
|
coronavirus |
4 |
|
cost-benefit analysis |
4 |
|
cost-effectiveness |
4 |
|
crf01-ae |
4 |
|
d614g |
4 |
|
drug resistance, viral - genetics |
4 |
|
effective reproduction number |
4 |
|
epidemics |
4 |
|
female |
4 |
|
fitness |
4 |
|
gastrointestinal bleeding |
4 |
|
general population |
4 |
|
genes, gag |
4 |
|
genes, pol |
4 |
|
h1n1 |
4 |
|
h2 |
4 |
|
healthcare workers |
4 |
|
hiv |
4 |
|
hiv infections - complications - epidemiology - virology |
4 |
|
hiv-1 - classification - drug effects - genetics |
4 |
|
hpv vaccination |
4 |
|
male |
4 |
|
molecular epidemiology |
4 |
|
nk cells |
4 |
|
older adults |
4 |
|
papillomavirus vaccines |
4 |
|
phylogeny |
4 |
|
population-based screening program |
4 |
|
pregnancy |
4 |
|
pregnancy complications, infectious - epidemiology |
4 |
|
prevalence |
4 |
|
proton pump inhibitors |
4 |
|
recombination, genetic |
4 |
|
sexual transmission |
4 |
|
social norm |
4 |
|
time trend |
4 |
|
vaccination decision making |
4 |
|
vaccine initiation |
4 |
|
young adult |
4 |
|
adverse weather |
3 |
|
antibody titer |
3 |
|
antiviral agents - therapeutic use |
3 |
|
blood donation |
3 |
|
blood donor |
3 |
|
blood inventory |
3 |
|
chinese |
3 |
|
colonoscopy |
3 |
|
convalescent |
3 |
|
cost analysis |
3 |
|
disease outbreaks - prevention & control |
3 |
|
disease outbreaks - prevention and control |
3 |
|
donor |
3 |
|
efficiency |
3 |
|
equity |
3 |
|
family characteristics |
3 |
|
gastroscopy |
3 |
|
health expenditures |
3 |
|
health information |
3 |
|
health perception |
3 |
|
health policy |
3 |
|
herd immunity |
3 |
|
hong kong |
3 |
|
hong kong influenza |
3 |
|
hpv vaccines |
3 |
|
human papillomavirus (hpv) |
3 |
|
immunization programs |
3 |
|
immunization, passive |
3 |
|
infectiousness |
3 |
|
influenza a (h1n1) |
3 |
|
influenza a (h3n2) |
3 |
|
influenza in birds - immunology |
3 |
|
influenza vaccines |
3 |
|
influenza vaccines - administration and dosage - immunology |
3 |
|
influenza, human - drug therapy - prevention and control - transmission |
3 |
|
influenza, human - epidemiology - immunology - prevention and control - therapy |
3 |
|
influenza, human - epidemiology - prevention and control - transmission |
3 |
|
influenza, human - immunology |
3 |
|
influenza, human - prevention & control |
3 |
|
ivig |
3 |
|
mathematical model |
3 |
|
meta‐analysis |
3 |
|
non-communicable diseases |
3 |
|
oncology, chinese parents |
3 |
|
partially overlapping samples |
3 |
|
pathway analysis |
3 |
|
plasma |
3 |
|
plasma - immunology |
3 |
|
plasmapheresis |
3 |
|
psoriasis |
3 |
|
public health administration |
3 |
|
qualitative methods |
3 |
|
resource allocation |
3 |
|
respiratory infection |
3 |
|
risk factors |
3 |
|
sars-cov |
3 |
|
school closure |
3 |
|
sexual mixing |
3 |
|
staging |
3 |
|
susceptibility |
3 |
|
temperature |
3 |
|
theory of planned behaviour |
3 |
|
united states |
3 |
|
united states dept. of health and human services |
3 |
|
vaccination intention |
3 |
|
acute lower respiratory infection |
2 |
|
allergology and immunology medical sciences |
2 |
|
big data |
2 |
|
cardiovascular diseases |
2 |
|
cis‐eqtl mapping |
2 |
|
classification |
2 |
|
communicable disease |
2 |
|
coxsackievirus a16 |
2 |
|
data science |
2 |
|
disaster planning |
2 |
|
enterovirus 71 |
2 |
|
epidemiological control |
2 |
|
gene expression |
2 |
|
hand, foot and mouth disease |
2 |
|
infectious disease |
2 |
|
influenza vaccines - therapeutic use |
2 |
|
influenza, human - epidemiology - prevention and control - virology |
2 |
|
least‐squares kernel machine |
2 |
|
maternal immunisation |
2 |
|
mathematical modelling |
2 |
|
mathematical models |
2 |
|
monoclonal antibody |
2 |
|
multiple variants |
2 |
|
nonavalent vaccine |
2 |
|
paediatric immunisation |
2 |
|
penalized |
2 |
|
public health |
2 |
|
respiratory syncytial virus |
2 |
|
transmission dynamic model |
2 |
|
a(h1n1)pdm09 |
1 |
|
adenoviridae - physiology |
1 |
|
adenovirus infections, human - complications - immunology - virology |
1 |
|
algorithms |
1 |
|
animals |
1 |
|
antineoplastic agents - administration & dosage - toxicity |
1 |
|
betacoronavirus |
1 |
|
brain neoplasms - drug therapy - pathology |
1 |
|
cell division - drug effects |
1 |
|
cell division - physiology - radiation effects |
1 |
|
cell growth processes - immunology |
1 |
|
cell hypoxia - physiology - radiation effects |
1 |
|
comparative study |
1 |
|
computer simulation |
1 |
|
coronavirus infection |
1 |
|
cross‐reactive antibodies |
1 |
|
cumulative incidence |
1 |
|
dna repair |
1 |
|
dose fractionation |
1 |
|
dose-response relationship, radiation |
1 |
|
drug delivery systems - methods |
1 |
|
drug design |
1 |
|
dynamic optimization |
1 |
|
dynamic programming |
1 |
|
economic evaluation |
1 |
|
epidemiological monitoring |
1 |
|
eq-5d |
1 |
|
exotoxins - administration & dosage - toxicity |
1 |
|
forecasting |
1 |
|
gene therapy - methods |
1 |
|
glioma - drug therapy - pathology |
1 |
|
h1n1pdm |
1 |
|
head and neck neoplasms - complications - immunology - pathology - virology |
1 |
|
health care |
1 |
|
health related quality of life |
1 |
|
hpv |
1 |
|
human |
1 |
|
immunology |
1 |
|
incidence |
1 |
|
influenza a virus, h1n1 subtype - drug effects |
1 |
|
influenza, human - drug therapy - epidemiology - prevention and control - virology |
1 |
|
infusions, intralesional |
1 |
|
interleukin-4 - administration & dosage - toxicity |
1 |
|
linear models |
1 |
|
linear-quadratic |
1 |
|
models, immunological |
1 |
|
models, theoretical |
1 |
|
neoplasms - therapy - virology |
1 |
|
neoplasms - virology |
1 |
|
oncogenic viruses - physiology |
1 |
|
oxygen consumption - physiology - radiation effects |
1 |
|
radiation tolerance |
1 |
|
radiobiology |
1 |
|
radiotherapy, computer-assisted |
1 |
|
recombinant fusion proteins - administration & dosage - toxicity |
1 |
|
relative biological effectiveness |
1 |
|
reoxygenation |
1 |
|
repair |
1 |
|
replicative senescence |
1 |
|
repopulation |
1 |
|
spheroids, cellular |
1 |
|
spheroids, cellular - pathology - physiology - radiation effects |
1 |
|
stochastic processes |
1 |
|
virus physiological phenomena |
1 |
|
virus replication |
1 |
